CONTINUE TO SITE

OR WAIT null SECS

Carl Zeiss Case Studies High-Frequency Deep Sclerotomy A MIGS Procedure for Mild-to-Moderate Glaucoma iCare COMPASS Automated Perimeter

Carl Zeiss Case Studies High-Frequency Deep Sclerotomy A MIGS Procedure for Mild-to-Moderate Glaucoma iCare COMPASS Automated Perimeter

View More Cataract & Refractive Cornea Gene Therapy Glaucoma Inflammation & Infection Paediatrics Retina

Cataract & Refractive Cornea Gene Therapy Glaucoma Inflammation & Infection Paediatrics Retina

Medical World News

Eyeviews Medical World News Podcasts Rapid Readouts Viewpoints

Digital Edition

Supplements And Featured Publications

Digital Edition Supplements And Featured Publications

Conference Coverage

Conference Listing

Sponsored Resources

Zeiss Case Studies

Sponsored Resources Zeiss Case Studies

Print Subscription

eNewsletter Print Subscription

Advertise
Editorial Info
Contact Us
Terms and Conditions
Privacy
Do Not Sell My Personal Information

© 2022 MJH Life Sciences and Opthalmology Times Europe. All rights reserved.

.navbar .collapse { display: block; } .mobile-nav { max-height: none !important; } @media screen and (min-width: 1200px) { .navbar #basic-navbar-nav .navbar-nav { position: static !important; } }

Spotlight

Carl Zeiss Case Studies
High-Frequency Deep Sclerotomy A MIGS Procedure for Mild-to-Moderate Glaucoma
iCare COMPASS Automated Perimeter

ClinicalSee All >

Cataract & Refractive
Cornea
Gene Therapy
Glaucoma
Inflammation & Infection
Paediatrics
Retina

Advertise
Editorial Info
Contact Us
Terms and Conditions
Privacy
Do Not Sell My Personal Information

© 2022 MJH Life Sciences^™ and Opthalmology Times Europe. All rights reserved.

Practice management in the era of anti-VEGF therapy (Part I)

May 1, 2007

Identifying the bottlenecks that are preventing effective management of neovascular AMD.

Related Content:

RetinaSponsored Resources

No negative effects in DMO patients reported following pandemic-imposed health care restrictions

No negative effects in DMO patients reported following pandemic-imposed health care restrictions

Risk factors for developing rhegmatogenous retinal detachments in fellow eyes identified in study

Risk factors for developing rhegmatogenous retinal detachments in fellow eyes identified in study

Pooled TENAYA, LUCERNE Phase 3 data reports safety, efficacy, lower treatment burden with faricimab for nAMD

Pooled TENAYA, LUCERNE Phase 3 data reports safety, efficacy, lower treatment burden with faricimab for nAMD